02:11 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Pathways emerging from ASH

A survey of the emerging molecular targets at this year’s American Society of Hematology conference indicates that while harnessing the immune system to treat cancer remains a dominant interest, processes for tuning protein levels --...
02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
07:00 , Aug 15, 2016 |  BioCentury  |  Emerging Company Profile

Restraining translation

Bantam Pharmaceutical LLC is developing small molecule eukaryotic translation initiation factor 4E inhibitors that selectively inhibit translation of several tumor-promoting genes and disrupt cancer cell metabolism. It hopes to show the mechanism of its lead...
08:00 , Jan 4, 2016 |  BioCentury  |  Finance

Effector's expansion

Effector Therapeutics Inc. had planned to complete a Phase I/II trial of eFT508 with existing cash, but preclinical data showing the compound's activity in a wide range of tumor types persuaded investors to back a...
07:00 , Oct 2, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Multiple myeloma (MM) Eukaryotic translation initiation factor 4F (eIF4F) Cell culture studies suggest inhibiting eIF4F activity could help improve the efficacy of dexamethasone therapy in...
07:00 , Sep 18, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer BRAF; eukaryotic translation initiation factor 4A1 (eIF4A1); eIF4F; MEK Studies in patient samples, mice and cell culture suggest disrupting the eIF4F complex could be...
07:00 , Sep 11, 2014 |  BC Innovations  |  Cover Story

Kinase convergence on eIF4F

Researchers in France have shown that resistance to BRAF and MEK inhibitors in melanoma and possibly other cancers can be driven by pathways that converge on the eukaryotic translation initiation factor 4F complex. 1 The...
08:00 , Jan 27, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Eukaryotic translation initiation factor 4F (eIF4F) In vitro and mouse studies identified an inhibitor of the eIF4F complex that could lower the resistance of...
08:00 , Feb 4, 2008 |  BC Week In Review  |  Company News

Egenix, Harvard deal

The university granted Egenix exclusive rights to cancer compounds and prognostic markers for various cancers. The small molecule inhibitors of the eukaryotic translation initiation factor 4F (eIF4F) and eIF2/met-tRNA ternary complex, two regulators of mRNA...